Combination therapy for a specific type of lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have newly diagnosed DLBCL with a TP53 gene mutation
- You are able to perform daily activities with little or no help (ECOG score 0-2)
- Your heart pumps enough blood (LVEF greater than 45%)
- If you have a history of hepatitis B, it must be inactive and your virus levels must be undetectable before starting the trial
- Your liver and kidneys function adequately, and you are expected to live at least 6 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medications for adults aged 60 and older with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a new combination of three drugs for people recently diagnosed with a type of lymphoma called large B-cell lymphoma. The goal is to see if this combination is safe and effective, and it might offer a new treatment option.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This study tests a new treatment combination (CD-RCHOP, likely a form of chemotherapy with an antibody) for people with a high-risk type of diffuse large B-cell lymphoma that has certain genetic changes (TP53 mutation and 17p deletion). It aims to see if this approach is safe and effective for this specific group.
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new TP53 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.